Dihexa Safety Profile

Safety Overview

FDA Approval Status: Not approved. Not in clinical trials. No Investigational New Drug (IND) application on record.

Level of Evidence: Very low. Zero human safety data. All published research consists of rodent studies conducted primarily at Washington State University (2012-2017). This peptide has never been tested in humans.

Research Status: Early-stage preclinical compound developed as a hepatocyte growth factor (HGF) mimetic for cognitive enhancement.

What We Don’t Know (Critical Gaps)

Unknown Factor	Why It Matters
Human pharmacokinetics	No data on absorption, distribution, metabolism, or excretion in humans
Human effective dose	Rodent doses cannot be reliably extrapolated to humans
Acute toxicity	No maximum tolerated dose established in any species
Long-term effects	Longest rodent study was 5 weeks; no chronic toxicity data
Drug interactions	Completely unknown
Reproductive toxicity	No studies on fertility, pregnancy, or development
Carcinogenic potential	HGF/c-Met pathway activation raises serious concerns (see below)

Theoretical Safety Concerns

HGF/c-Met Pathway Activation

Critical Risk: Dihexa is a potent agonist of the hepatocyte growth factor (HGF) system, active at picomolar concentrations (10⁻¹² M). The HGF/c-Met signaling pathway is heavily implicated in cancer biology.

Cancer Concerns:

• c-Met receptor overexpression found in many human cancers
• HGF promotes tumor cell proliferation, invasion, and metastasis
• c-Met is a validated oncology drug target—drugs that BLOCK this pathway are in clinical trials for cancer treatment
• Dihexa does the opposite: it activates this pathway

Unknown: Whether dihexa’s specific binding mechanism produces the same tumorigenic effects as endogenous HGF. No cancer studies have been conducted.

Extreme Potency

Dihexa is 7 orders of magnitude more potent than brain-derived neurotrophic factor (BDNF) in rodent cognitive assays. This extreme potency raises safety concerns:

• Very narrow therapeutic window (small difference between effective and toxic doses)
• Difficult to accurately dose at microgram scales
• Potential for off-target effects at low concentrations

Blood-Brain Barrier Penetration

Dihexa crosses the blood-brain barrier efficiently—this is the intended mechanism. However, it also means systemic administration results in direct CNS exposure with unknown consequences.

Rodent Study Observations

Published animal studies reported no overt toxicity at doses tested (typically 0.5-2 mg/kg in rodents). However:

• Studies were short-term (1-5 weeks)
• Small sample sizes (n=6-12 per group)
• Limited toxicology panels (primarily behavioral endpoints)
• No histopathology of tissues outside the brain

One study noted increased anxiety-like behavior in rodents at higher doses—potential psychiatric side effect signal.

Known Risks in Current Use

Despite lack of approval, dihexa is available from research chemical suppliers and used by biohackers.

Documented Issues:

• Dosing inconsistency: User reports range from 0.5 mg to 5 mg subcutaneously—10-fold variation
• Adverse effects reported: Anxiety, irritability, insomnia, headaches (anecdotal, unverified)
• Product purity concerns: No pharmaceutical-grade source exists; purity unknown

Contraindications (Theoretical)

Based on mechanism of action, dihexa should likely be avoided in:

• Active cancer or history of cancer (absolute contraindication due to HGF/c-Met activation)
• Pregnancy and lactation (no developmental toxicity data)
• Psychiatric disorders (anxiety signal in rodent studies)
• Hepatic or renal impairment (unknown metabolism/excretion)

Risk Assessment: HIGH RISK

Dihexa represents one of the highest-risk peptides in current biohacker use due to:

1. Zero human data (never tested in clinical trials)
2. Potent activation of cancer-associated pathway (HGF/c-Met)
3. No long-term safety studies in any species
4. Extreme potency (difficult to dose safely)
5. No pharmaceutical-grade product available

Dihexa has never been tested in humans. All safety information is theoretical, based on mechanism of action and limited rodent studies. The activation of the HGF/c-Met pathway—a validated cancer drug target—represents a serious and unquantified long-term risk. Use of this compound is NOT supported by any credible safety data.